Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnSquareMore

News

Stay up to date on the latest crypto trends with our expert, in-depth coverage.

banner
Flash
09:09
E Fund Crude Oil LOF: Trading Suspended Until 10:30 on April 7
Golden Ten Data reported on April 6 that E Fund Oil Securities Investment Fund (QDII) announced that the fund's secondary market trading price is significantly higher than the fund unit net value. The net value on April 1 was 1.6320 yuan, and the closing price on April 3 was 2.213 yuan. Investors are reminded to pay attention to premium risk and avoid buying at high prices. Trading will be suspended from the market opening on April 7 until 10:30 (UTC+8), and will resume at 10:30 (UTC+8). Redemption services will continue as usual during the suspension. If the premium does not fall back, further measures will be taken to warn of risk. Fund operations are normal at present, and there is no undisclosed information that should have been disclosed.
09:08
Oil Fund LOF: Trading will be suspended from market open until 10:30 on April 7.
Golden Ten Data reported on March 31 that GF Fund Management Co., Ltd. announced its GF Dow Jones U.S. Oil Exploration & Production Index Securities Investment Fund (QDII-LOF) (Fund Code: 162719, trading abbreviation: 石油LOF) will be suspended from the market starting on April 7, 2026, until 10:30 a.m. (UTC+8) on the same day, and will resume trading at 10:30 a.m. (UTC+8) on April 7, 2026.
09:03
Reports indicate that Neurocrine Biosciences is about to acquire Soleno Therapeutics at a price of approximately $2.5 billions, prompting Soleno Therapeutics' shares to surge 30% in pre-market trading.
The market responded enthusiastically to this potential deal, reflecting investors' positive expectations for the strategic integration prospects of the two companies. If this acquisition is successfully completed, it will become a significant merger and acquisition case in the neuroscience field in recent years. By integrating Soleno Therapeutics' R&D pipeline, Neurocrine Biosciences is expected to strengthen its position in the central nervous system therapeutics sector. The significant increase in pre-market trading volume also demonstrates the capital market's high level of attention to industry resource integration.
News